Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.